DALISOON F.C. TABLETS 5MG

TABLET, FILM COATED

**DOSAGE AND ADMINISTRATION** _Adults, including the elderly_ The recommended dose is 5 mg solifenacin succinate once daily. If needed, the dose may be increased to a maximum of 10 mg solifenacin succinate once daily. _Children and adolescents_ Solifenacin succinate is not indicated for treatment of OAB in the pediatric population. **Special populations** _Patients with renal impairment_ No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance >30 ml/min). Patients with severe renal impairment (creatinine clearance ≤30 ml/min) should be treated with caution and receive no more than 5 mg once daily. _Patients with hepatic impairment_ No dose adjustment is necessary for patients with mild hepatic impairment. Patients with moderate hepatic impairment (Child-Pugh B) should be treated with caution and receive no more than 5 mg once daily. Dalisoon is not recommended for patients with severe hepatic impairment (Child-Pugh C). _Co-medication_ The maximum dose of Dalisoon should be limited to 5 mg when treated simultaneously with ketoconazole or therapeutic doses of other potent CYP3A4- inhibitors e.g. ritonavir, nelfinavir, itraconazole, cyclosporin, macrolide antibiotics (see also INTERACTIONS WITH OTHER DRUGS – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Method of administration** Dalisoon should be taken orally and should be swallowed whole with liquids. It can be taken with or without food.